Latest news with #CFRA
Yahoo
10 hours ago
- Business
- Yahoo
CFRA Hikes Price Target on Trip.com (TCOM), Maintains Hold Rating
On Tuesday, CFRA analyst Siti Salikin raised the price target on Group Limited (NASDAQ:TCOM) to $65 from $60 while citing the stock's five-year P/E average of 41. Additionally, the analyst reiterated a Hold rating on the stock on concerns that the company's revenue growth will slow down to 14.8% in 2025. The growth rate is also expected to slow in 2026 to 13.5%. Nevertheless, the analyst remains optimistic about the company's long-term prospects owing to the anticipated resurgence of domestic travel and international tourism. The analyst also expects to benefit from visa-free policies between China and other countries. A recovery of cross-border flight capacities is also likely to strengthen the company's revenue base. is increasingly expanding into lower-tier cities in China. It's also broadening its range of product offerings as it seeks to unlock new growth opportunities. The only downside to the expansion drive is the expected spike in sales and marketing expenses. Increased operational costs are expected to trigger a dip in net margin in 2025. The company delivered solid first-quarter 2025 results. Revenue was up 16.2% year-over-year to 13.8 billion yuan as operating profit totaled 3.56 billion yuan, aligning with analysts' estimates. reported 3.56 billion yuan in operating profit, though its 80.4% gross margin dipped due to increased revenue from its own services. The company maintains a mid-teens growth forecast for Q2 and FY2025, fueled by rising international travel demand. Group Limited is a global travel platform that offers a wide range of travel products and services, including accommodation, flights, and other travel-related services. As a top choice in Asia and expanding worldwide, it helps travelers explore destinations, book cost-effective trips, access real-time support, and share experiences operates Ctrip, Qunar, and Skyscanner, driven by its mission: "To pursue the perfect trip for a better world." While we acknowledge the potential of Group Limited (NASDAQ:TCOM) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TCOM and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
a day ago
- Business
- Business Insider
CFRA Sticks to Its Hold Rating for Trip.com Group Sponsored ADR (TCOM)
CFRA analyst Siti Salikin maintained a Hold rating on Group Sponsored ADR (TCOM – Research Report) today and set a price target of $65.00. The company's shares closed today at $61.75. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Salikin is a 3-star analyst with an average return of 21.3% and a 57.14% success rate. Currently, the analyst consensus on Group Sponsored ADR is a Strong Buy with an average price target of $77.00. The company has a one-year high of $77.18 and a one-year low of $38.23. Currently, Group Sponsored ADR has an average volume of 4.19M.
Yahoo
5 days ago
- Business
- Yahoo
Why Five Below Stock Got Socked Today
The company was hit with a recommendation downgrade. This downgrade happened despite management's recent raising of first-quarter guidance. 10 stocks we like better than Five Below › Teen- and "tween"-focused discount retailer Five Below (NASDAQ: FIVE) saw its stock head south on Friday after a researcher downgraded its recommendation on the company. While this didn't exactly tank the stock, it did leave it with a 2.5% decline on the last trading session of the week. By contrast, the benchmark S&P 500 index suffered only a mild fall with a 0.4% slide on the day. That researcher, CFRA, changed its recommendation to hold from buy, tagging Five Below with a price target of $108. Neither the details of the change nor the reasoning behind it were immediately apparent. It came less than two weeks before Five Below is slated to release its first quarter of fiscal 2026 earnings. As a group, analysts tracking the company are still expecting it to show some solid growth for the period. They are collectively modeling a 19% year-over-year improvement in sales to $966 million and believe per-share earnings will pop by 38% to $0.83. At least some of this optimism stems from the company's guidance raise in early May. It significantly lifted its own estimate for Q1 sales to roughly $967 million (essentially in line with that analyst consensus) from the previous forecast of $905 million to $925 million. That's on a foundation of anticipated same-store sales growth of 6.7%, well up from the former projection of flat to 2%. Five Below didn't outline its reasons for the rather strong increases in guidance items, so when that earnings report is published, it should be at least somewhat enlightening. Regardless, the tariff war isn't quite as nasty as some feared it would be, and consequently, the impact on our economy shouldn't be too negative. It might just be time to snap up shares of a retailer like Five Below. Before you buy stock in Five Below, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Five Below wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $640,662!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $814,127!* Now, it's worth noting Stock Advisor's total average return is 963% — a market-crushing outperformance compared to 168% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Five Below. The Motley Fool has a disclosure policy. Why Five Below Stock Got Socked Today was originally published by The Motley Fool
The Star
6 days ago
- Business
- The Star
UnitedHealth share price plunge stuns Wall Street
NEW YORK: When CFRA's Paige Meyer slapped a 'sell' rating on UnitedHealth Group Inc in February, she was the lone analyst out of 30 tracked by Bloomberg with a negative view of the company. Meyer's price target implying a 22% fall for the shares glared in a sea of optimistic forecasts, while her warnings on regulatory uncertainty and high medical expenses seemed almost alarmist. The health insurance giant was, after all, an industry bellwether that was widely considered a safe bet by Wall Street, even as it faced rising costs and was recovering from the murder of a top executive last year. Today, Meyer's outlook has proved more prescient than she could have imagined. UnitedHealth's stock has plunged about 40% since her downgrade to Wednesday's close, losing more than US$187bil in market value and notching a spot as the worst performer in the S&P 500 Index during that period. The tumble came as the company cut – then suspended – its annual forecast, replaced its chief executive officer and is now reportedly facing a criminal investigation for possible Medicare fraud. 'I feel fortunate that I had the courage to make that call,' Meyer said in an interview. 'It's hard to go against the grain.' More bad news continues to pile up for UnitedHealth. The Guardian reported Wednesday that the insurer secretly paid nursing homes bonuses to cut hospital transfers for sick residents, as part of a series of cost-cutting tactics. Prior to that, HSBC cut the stock to a sell-equivalent rating, becoming the second analyst tracked by Bloomberg to do so. UnitedHealth shares dropped 5.8% on Wednesday. The crisis at UnitedHealth is resurfacing an issue that has long plagued Wall Street: The overwhelmingly positive views analysts hold on America's biggest corporations. Data compiled by Bloomberg show that nearly 60% of ratings on S&P 500 companies are 'buys,' and only 5% are 'sells.' UnitedHealth was an extreme example of the trend when Meyer slashed her rating, sporting the highest ratio of 'buys,' at 97%. Some of the reasons behind those bullish outlooks have little to do with company fundamentals, market participants said. Analysts may hesitate to be overly critical of a company for fear of hurting their relationship with management, which can mean less face time with executives, said Rhys Williams, chief strategist at Wayve Capital Management LLC and a nearly four-decade veteran of Wall Street. Many also work at firms that make a hefty chunk of their profits from investment banking – an area that is typically firewalled from its research arm. Still, analysts are wary of being negative on companies that might be current or future clients, said David Miller, co-founder and CIO at Catalyst Funds. 'For the most part, they don't want to get fired,' he said. 'Investment banks aren't charities, so they want business from these same companies.' The collapse of Silicon Valley Bank two years ago is a recent example of analysts being blindsided by weakness in a company's fundamentals. To what degree such factors played a role in the coverage of UnitedHealth is hard to say. Its proponents, to be sure, often cited the firm's dominant industry position and its history of stellar performance. The insurer regularly reported quarterly profit that beat estimates, and its stock surged more than 1,800% from its 2008 plunge through the end of 2024. 'The view has been 'it's the best-run company, it has the best management and it's huge in the benchmark, so I'm just gonna set it and forget it',' said Mike Taylor, lead portfolio manager of Simplify Health Care ETF, which has maintained an underweight position in UnitedHealth shares. A UnitedHealth spokesperson said the company 'strives to be accessible to a wide range of analysts and investors, including those with varying perspectives and ratings.' UnitedHealth's issues with rising medical costs began two years ago, as patients who had put off elective procedures during the Covid-19 pandemic started seeking care. The company reassured investors in January, saying it had adequately prepared to cover medical costs trends for 2025. CFRA's Meyer wasn't convinced. Besides the threat posed by rising costs, she was alarmed by reports of a US Justice Department civil investigation into UnitedHealth's Medicare billing practices, as well as concerns over plans by the Trump administration to cut costs in federal insurance programmes. She downgraded the company to 'sell' on Feb 21. Other analysts were sanguine. A bevy of Wall Street banks, from JPMorgan Chase & Co to Wells Fargo & Co, maintained positive ratings on the health insurer going into its April 17 earnings report. The stock rose 25% in the nearly two-month span between Meyer's downgrade and the company's first-quarter earnings. JPMorgan analyst did not respond to a request for comment on this story. Wells Fargo analyst declined to comment. What happened next stunned analysts and investors. Medical costs were rising faster than it had anticipated, the company said. UnitedHealth reported its first profit shortfall since 2008 and cut its annual forecast as a result. 'We did speak to the company and all signs were pointing to the first quarter being a solid setup,' said Michael Ha, an analyst at Baird. 'It's a complete shock and I just don't see how anyone could have foreseen all of this happening.' — Bloomberg
Bloomberg
21-05-2025
- Business
- Bloomberg
UnitedHealth Group Downgraded to Sell at CFRA
CFRA analyst Paige Meyer downgraded UnitedHealth Group Inc. to "sell" in February, predicting a 22% fall in shares, which has since plunged 36% and lost $170 billion in market value. It's the latest in a string of negative moves for the stock. Denitsa Tsekova reports. (Source: Bloomberg)
